UK NICE recommends use of Stivarga (regorafenib) in adults with gastrointestinal stromal tumours.- Bayer HealthCare.
The UK National Institute for Health and Care Excellence has backed Stivarga (regorafenib), from Bayer Healthcare, as a cost-effective option for the treatment of adults with gastrointestinal stromal tumours (GIST). In final draft guidance, NICE has approved routine funding for the drug on the NHS to treat patients with the condition who progressed on or are intolerant to prior treatment with imatinib and sunitinib. Stivarga has been available on the Cancer Drugs Fund since 2013, but with this latest decision will switch into the NHS’ normal commissioning stream.
According to NICE, evidence shows Stivarga can extend a patient’s life by more than nine months compared to best available care, the current alternative for people with this form of cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.